OneMedNet Stock Price, News & Analysis

OneMedNet (Nasdaq: ONMD), a provider of regulatory-grade imaging Real-World Data, has secured $3.7 million in funding through private placement transactions at $0.42 per share. The company has also significantly improved its financial position by reducing liabilities by approximately $11 million, representing a 60% reduction in total liabilities as of March 31, 2025.

The liability reduction includes settling $3.26 million in deferred underwriter fees, $1.08 million in trade payables, converting $6.56 million of principal and interest into common stock, and redeeming $250,000 in convertible notes. The company plans to use the new funding for working capital and general corporate purposes, while continuing its strategy of adding Bitcoin to its balance sheet.

OneMedNet (NASDAQ: ONMD), a provider of imaging Real-World Data (iRWD), has announced enhanced capabilities through the Datavant Connect platform and AWS Clean Rooms to improve healthcare data discovery and analytics. The integration will enable secure data collaboration environments without direct data movement, significantly improving data security and privacy while facilitating faster identification and evaluation of healthcare datasets.

The announcement comes as the healthcare industry faces challenges with the growing volume of health-related data, including genomic sequencing and biomarker data. The new platform will be showcased at ISPOR 2025, demonstrating OneMedNet's commitment to providing secure, scalable data solutions for healthcare and life sciences organizations.

OneMedNet (Nasdaq: ONMD) has integrated its imaging Real-World Data (iRWD) solution into the HealthVerity Marketplace, expanding access to comprehensive healthcare data for life sciences research. OneMedNet's network encompasses over 1,400 healthcare systems with access to 121 million clinical exams from 31 million unique patients.

This integration allows researchers to combine imaging data with medical claims, pharmacy, lab, and EHR data, providing a more complete view of patient journeys. The HealthVerity platform connects data from over 340 million de-identified individuals in a HIPAA-compliant environment.

The partnership enhances evidence generation capabilities by adding visual confirmation of disease progression, diagnostic markers, and therapy responses to structured data analysis. This collaboration aims to support more informed clinical development and commercialization decisions in healthcare research.

OneMedNet (ONMD) has announced a strategic partnership with Protege, an AI training data platform, to provide real-time access to multimodal patient data for AI developers and researchers. The collaboration will make OneMedNet's comprehensive healthcare datasets available through Protege's platform.

The partnership aims to enhance AI model development by providing access to diverse clinical data, including medical imaging, electrocardiograms (ECG), electroencephalograms (EEG), and other modalities. OneMedNet's iRWD™ platform currently leverages data from over 1,400 healthcare sites, covering areas such as rare diseases, oncology, and cardiology.

The company's technology extends beyond healthcare, offering AI anonymization services for industries like finance, retail, and telecom, enabling secure sharing of sensitive data by removing personal information.

OneMedNet has announced a strategic collaboration with Datavant to enhance access to tokenized healthcare data through Datavant's ecosystem. The partnership leverages OneMedNet's extensive network of 31 million patients and 121 million+ clinical studies, including EMR insights, images, ECGs, and clinical notes.

The integration enables life sciences companies to combine claims data for comprehensive patient journey analysis across specific diseases. By incorporating OneMedNet's patient tokens into Datavant's network of over 300 real-world data partners, researchers can efficiently discover and access targeted Real-World Data for specific patient populations. This collaboration aims to improve longitudinal data visibility and connectivity while maintaining patient privacy, ultimately accelerating evidence-based healthcare solutions.

OneMedNet (Nasdaq: ONMD) has appointed Dr. Kenneth Alleyne to its Board of Directors, where he will serve as Chair of the Audit Committee. Dr. Alleyne, a board-certified orthopedic surgeon specializing in sports medicine, brings significant healthcare, insurance, and corporate governance expertise to the company.

Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm. His entrepreneurial background includes co-founding NextLevel Health Partners and Zing Healthcare, focusing on Medicaid and Medicare Advantage initiatives. He was also a seed investor and founding chief medical officer of VirtualHealth, and co-founder/CEO of Fizio Health, an AI-powered remote physical therapy platform.

The appointment aims to enhance OneMedNet's iRWD™ platform, strengthen relationships with medical device companies in orthopedics, and provide insurance companies with insights for cost savings, particularly in high-spend orthopedic care.

OneMedNet (ONMD) has regained compliance with Nasdaq Listing Rule 5550(b)(2) after its common stock market value exceeded $35,000,000 for 10 consecutive business days. The company has cleared all listing deficiency notices issued by Nasdaq.

Throughout 2024-2025, OneMedNet implemented several strategic initiatives, including: expanding product offerings with data masking solutions and subscription-based services; appointing key executives including Bob Golden as CFO; signing an agreement with Bayer's AI Innovation Platform; enhancing data de-identification services with Generative AI; deploying the OMNi 2.0 indexer; refreshing the Board of Directors; and improving liquidity through $6.4M in private placements with Off the Chain Capital and Discovery Capital Management affiliate. The company also implemented a Bitcoin treasury management strategy.

OneMedNet (ONMD) has successfully regained compliance with Nasdaq's minimum bid price requirement, maintaining a closing bid price of $1.00 or higher for 10 consecutive business days. The company has implemented several strategic initiatives in the second half of 2024, including key executive appointments such as Bob Golden as CFO, Margaret Nash as Director of Business Development, and Michael Wong as VP of Marketing.

The company has enhanced its operations by improving its Data De-Identification service with Generative AI, deploying the OMNi 2.0 indexer, and signing an agreement with Bayer's AI Innovation Platform. Financial improvements include raising approximately $6.4M through private placements with Off the Chain Capital and Discovery Capital Management affiliate, alongside implementing a Bitcoin treasury management strategy.

OneMedNet (ONMD) has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its quarterly reports for Q1, Q2, and Q3 2024. During H2 2024, the company executed several strategic initiatives including: appointing Bob Golden as interim CFO, hiring key commercial positions, signing an agreement with Bayer's AI Innovation Platform, enhancing data services with AI, refreshing the Board of Directors, and improving liquidity through $6.4M in private placements. The company also implemented a Bitcoin treasury management strategy and enhanced its OMNi indexer technology for improved data searching capabilities.